Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | SLC6A6 | P31641 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | BLM | P54132 | 1/20 | 0.55 |
| ▸ | APP | P05067 | 1/20 | 0.50 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.42 |
| ▸ | PDE4A | P27815 | 1/20 | 0.42 |
| ▸ | CXCL10 | P02778 | 1/20 | 0.30 |
| ▸ | CXCL8 | P10145 | 1/20 | 0.30 |
| ▸ | CCL2 | P13500 | 1/20 | 0.30 |
| ▸ | CCL5 | P13501 | 1/20 | 0.30 |
| ▸ | CXCL12 | P48061 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16329223 | 0.98 | LMNA (0.52) | LMNASLC6A6CYP2C19BLMAPP | |
| SCHEMBL418534 | 0.87 | PTGS1 (0.53) | LMNASLC6A6CYP2C19BLMAPP | |
| SCHEMBL9988925 | 0.84 | APP (0.56) | LMNASLC6A6CYP2C19BLMAPP | |
| Sulfuric Acid SCHEMBL8719034 | 0.84 | BLM (0.43) | LMNASLC6A6CYP2C19BLMAPP | |
| SCHEMBL7869938 | 0.84 | PTGS1 (0.50) | LMNASLC6A6CYP2C19BLMAPP | |
| SCHEMBL28038731 | 0.84 | PTGS1 (0.50) | LMNASLC6A6CYP2C19BLMAPP | |
| SCHEMBL3488844 | 0.80 | PTGS1 (0.42) | LMNASLC6A6CYP2C19BLMAPP | |
| SCHEMBL8495567 | 0.78 | LMNA (0.36) | LMNASLC6A6CYP2C19BLMAPP | |
| SCHEMBL263732 | 0.77 | APP (0.46) | LMNASLC6A6CYP2C19BLMAPP | |
| SCHEMBL375597 | 0.77 | TSHR (0.53) | LMNASLC6A6CYP2C19BLMAPP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230131121-A1 | BRANCHED DISCRETE PEG CONSTRUCTS | AUDAX PRIVATE DEBT LLC, AS AGENT | 2023-04-27 | — | — | US | disclosed |
| EP-0628860-B1 | New type of modified gelatin and its use in a DTR material | AGFA GEVAERT NV (BE) | 1997-10-15 | — | — | EP | disclosed |
| US-5536817-A | DIFFUSION TRANSFER REVERSAL | AGFA-GEVAERT, N.V. (BE) | 1996-07-16 | — | — | US | disclosed |
| US-5474885-A | Hydrophilic photographic diffusion transfer reversal material containing gelatin modified by sulfate, sulfonate, phosphate, or phosphonate groups, for lithographic printing plates | AGFA-GEVAERT, N.V. (BE) | 1995-12-12 | — | — | US | disclosed |
| EP-0628860-A1 | New type of modified gelatin and its use in a DTR material | AGFA-GEVAERT N.V. (BE) | 1994-12-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230131121-A1 | BRANCHED DISCRETE PEG CONSTRUCTS | BTD, IDUA, DNPEP | LMNA 1957/4885SLC6A6 4381/4885CYP2C19 1671/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.